Please ensure Javascript is enabled for purposes of website accessibility

Fresno City Gets Extension in Herndon 4-Story Apartment Case

1 day ago

With Major Heat Risk Forecast, This Is a Good Weekend to Stay Indoors in Fresno

1 day ago

Trump Says Intel Has Agreed to Deal for US to Take 10% Equity Stake

1 day ago

Epstein Associate Maxwell Says She Never Saw Trump Behave Inappropriately

1 day ago

Pew: US Immigrant Population Declines for First Time in Nearly 60 Years

1 day ago

Powell, Citing Jobs Risk, Opens Door to Cuts but Doesn’t Commit

2 days ago

FBI Agents Search Ex-Trump Adviser Bolton’s Home, Source Says

2 days ago

Gaza City Officially in Famine, With Hunger Spreading, Says Global Hunger Monitor

2 days ago

Gavin Newsom’s Redistricting Plan Is on Its Way to Voters. What You Need to Know

2 days ago
Experimental COVID-19 Drug Cleared for Clinical Trials at Northern California Hospital
TLBBHMAP3-U010ALB5ANM-348f959abae2-512-300x300-1
By Jim Jakobs, Digital Producer
Published 5 years ago on
April 9, 2020

Share

“A promising investigational drug.”
Those words are being written quite a bit during these days as politicians, scientists, and the general public explore avenues for combating the COVID-19 pandemic.
Those same words were used in a press release from Saint Joseph Hospital in Humbolt County in announcing their participation in a new clinical trial of a drug developed by California-based Gilead Sciences.

Clinical Trials of Anti-Viral Drug Remdesivir

St Joseph Hospital in Eureka said in a news release that it is participating in two national clinical trials of the anti-viral drug remdesivir for the treatment of moderate and severe COVID-19. The experimental drug has shown promise in some recent emergency uses and patient trials.
“This is an important opportunity for future patients who present with COVID–19 at St. Joseph Hospital and meet certain criteria, to have access to remdesivir, a promising investigational drug,” said Dr. Roberta Luskin-Hawk, St. Joseph’s chief executive.
The hospital was chosen due to an established relationship with the principal investigator of the trial and was proactive in seeking accelerated approval for the trials in Humboldt.
Interest has been so great in remdesivir that the U.S. National Institutes of Health is expanding its study, which has nearly reached its initial goal of 440 patients. The NIH study is the most rigorous test. It compares remdesivir to placebo infusions, with neither patients nor doctors aware of who is getting which treatment until the end of the study.

How Remdesivir Works

Remdesivir is given through an IV. It’s designed to interfere with an enzyme that reproduces viral genetic material.
In animal tests against SARS and MERS, diseases caused by similar coronaviruses, the drug helped prevent infection and reduced the severity of symptoms when given early enough in the course of illness. It’s farther along in testing than many other potential therapies and current studies could lead to regulatory approval.
Online medical news site Stat News describes remdesivir this way: “The drug is designed to interfere with the process the virus, called SARS-CoV-2, uses to make copies of itself. The resulting copies of the virus lack their full RNA genome, so they can’t go on to replicate themselves or infect other cells.”
[covid-19-tracker]

‘Compassionate Use’ Allowed Under Emergency Regulations

In addition to patient trials, the U.S. Food and Drug Administration has authorized the use of remdesivir for treatment in a limited number of “compassionate use” cases.
“Gilead has given remdesivir to more than 1,700 patients on a case-by-case emergency basis, but more people ultimately will be helped if the company does the needed studies to prove safety and effectiveness,” Gilead chief executive Dan O’Day wrote in a open letter on the company’s website.
O’Day said the company has an inventory of 1.5 million doses, which could mean more than 140,000 treatment courses, depending on how long treatment needs to last. The company is providing the drug for free for now and has set a goal of making 500,000 treatment courses by October and more than a million by the end of the year.
Gilead supplied remdesivir for two studies in China expected to give results by the end of the month. It also launched two studies for hospitalized patients in the U.S., Asia, Europe and elsewhere.

Rubber stoppers are placed onto filled vials of the investigational drug remdesivir at a Gilead manufacturing site. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP)

A Remdesivir Recap With Mention of a ‘Red Flag’

“Stat News” recently reported on the trials and what might come next.
“Sometime this month, Chinese scientists will share results from two trials in that country, one looking at patients with severe Covid-19, and one with patients with mild and moderate infections,” the website reported.
“There is already one red flag. The investigators running the severe COVID-19 study in China have already taken an interim look at the data, but they did not stop the study early,” Stat News noted. “This suggests remdesivir isn’t working as well as hoped, and dampens optimism for an overall positive outcome.
“It’s also possible the trial will produce mixed results.”

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Fresno State Bulldogs Can’t Find Answer for Daniels in Loss at Kansas

DON'T MISS

Hegseth Authorizes Troops in DC to Carry Weapons

DON'T MISS

Texas, Florida Seek to Join Legal Challenge to Abortion Pill

DON'T MISS

Wrongly Deported Migrant Abrego Released, May Be Detained Again

DON'T MISS

Judge Blocks Trump From Withholding Funds From Los Angeles, Other Sanctuary Cities

DON'T MISS

Lyle Menendez Denied Parole After 35 Years in Prison for Parents’ Shotgun Murders

DON'T MISS

California Cities Lack Unified Response On Homeless Encampments

DON'T MISS

Trump Crime Crackdown Deploys Troops in Washington’s Safest Sites

DON'T MISS

California Voters Still Support High-Speed Rail, Even If It Never Gets Done

DON'T MISS

Turkish First Lady Urges Melania Trump to Speak out on Gaza

UP NEXT

Judge Blocks Trump From Withholding Funds From Los Angeles, Other Sanctuary Cities

UP NEXT

California Cities Lack Unified Response On Homeless Encampments

UP NEXT

California Voters Still Support High-Speed Rail, Even If It Never Gets Done

UP NEXT

I Was Preyed On for My VA Benefits. California Can Stop It

UP NEXT

Pew: US Immigrant Population Declines for First Time in Nearly 60 Years

UP NEXT

Gavin Newsom’s Redistricting Plan Is on Its Way to Voters. What You Need to Know

UP NEXT

Fresno Doctor on Bubonic Plague: It’s Rare But It’s Out There. Prevention Is Key

UP NEXT

CARB Executive Leader Rips Trump’s EPA for Seeking to Kill Proven Climate Science

UP NEXT

California Lawmakers Advance First Two Bills in Democrats’ Redistricting Plan

UP NEXT

Trump Administration Cuts California Grant Over Transgender Policies

Wrongly Deported Migrant Abrego Released, May Be Detained Again

12 hours ago

Judge Blocks Trump From Withholding Funds From Los Angeles, Other Sanctuary Cities

12 hours ago

Lyle Menendez Denied Parole After 35 Years in Prison for Parents’ Shotgun Murders

12 hours ago

California Cities Lack Unified Response On Homeless Encampments

12 hours ago

Trump Crime Crackdown Deploys Troops in Washington’s Safest Sites

12 hours ago

California Voters Still Support High-Speed Rail, Even If It Never Gets Done

12 hours ago

Turkish First Lady Urges Melania Trump to Speak out on Gaza

12 hours ago

Fresno Crash Sends Car Into Building After Running Red Light

1 day ago

Fresno City Gets Extension in Herndon 4-Story Apartment Case

1 day ago

Atwater Prison Inmate Charged for Threatening to Kill Prosecutor’s Family

1 day ago

Fresno State Bulldogs Can’t Find Answer for Daniels in Loss at Kansas

The Bulldogs could not stop Jalon Daniels. If the Kansas sixth-year quarterback wasn’t accurately completing passes, he was running out of t...

39 minutes ago

39 minutes ago

Fresno State Bulldogs Can’t Find Answer for Daniels in Loss at Kansas

Soldiers with the 30th Armored Combat Brigade from the South Carolina National Guard at Union Station in Washington, Aug. 20, 2025. Defense Secretary Pete Hegseth has authorized National Guard troops deployed to Washington to bring their weapons with them on their mission. (Kenny Holston/The New York Times)
10 hours ago

Hegseth Authorizes Troops in DC to Carry Weapons

A patient prepares to take Mifepristone, the first pill in a medical abortion, at Alamo Women's Clinic in Carbondale, Illinois, U.S., April 9, 2024. (Reuters File)
12 hours ago

Texas, Florida Seek to Join Legal Challenge to Abortion Pill

Kilmar Abrego Garcia walks, after he has been released from the Putnam County Jail in Cookville, Tennessee, U.S., August 22, 2025. (Reuters/Seth Herald)
12 hours ago

Wrongly Deported Migrant Abrego Released, May Be Detained Again

U.S. flag and Judge gavel are seen in this illustration taken, August 6, 2024. (Reuters/Dado Ruvic/Illustration)
12 hours ago

Judge Blocks Trump From Withholding Funds From Los Angeles, Other Sanctuary Cities

Lyle Menendez attends his Board of Parole hearing online from the Richard J. Donovan Correctional Facility in San Diego, California, U.S., August 22, 2025, that could lead to freedom after decades in prison for the 1989 shotgun murders of his parents. The final decision will rest with the governor, who can either accept or reject the board's recommendation. California Department of Corrections and Rehabilitation/Handout via REUTERS
12 hours ago

Lyle Menendez Denied Parole After 35 Years in Prison for Parents’ Shotgun Murders

12 hours ago

California Cities Lack Unified Response On Homeless Encampments

Members of the Mississippi National Guard eat ice cream and boba tea on the National Mall after U.S. President Donald Trump deployed the National Guard and ordered an increased presence of federal law enforcement to assist in crime prevention, in Washington, D.C., U.S., August 21, 2025. (Reuters/Al Drago)
12 hours ago

Trump Crime Crackdown Deploys Troops in Washington’s Safest Sites

Search

Help continue the work that gets you the news that matters most.

Send this to a friend